The analysis plan included assessments that stratified by PD-L1 expression of patient tumor samples, and while 48% (13/27) of studies reported PD-L1 expression status, the testing methods and thresholds for PD-L1 expression status were not uniform, thereby precluding a meaningful stratified analysis. This evidence concerns the gene CD274 and neoplasm.